Provided by Tiger Trade Technology Pte. Ltd.

Bristol-Myers Squibb

67.01
+1.542.35%
Post-market: 67.020.0100+0.01%19:59 EDT
Volume:6.84M
Turnover:457.82M
Market Cap:136.42B
PE:14.75
High:67.55
Open:65.79
Low:65.13
Close:65.47
52wk High:68.64
52wk Low:42.52
Shares:2.04B
Float Shares:2.03B
Volume Ratio:0.72
T/O Rate:0.34%
Dividend:2.51
Dividend Rate:3.74%
EPS(TTM):4.54
EPS(LYR):3.46
ROE:46.60%
ROA:10.72%
PB:6.11
PE(LYR):19.37

Loading ...

Bristol Myers (BMY) Is Up 5.5% After FDA Accepts Mezigdomide NDA In Multiple Myeloma

Simply Wall St.
·
Jul 19

How Firms Hit Their Numbers by Any Means Necessary: Marty Fridson

Reuters
·
Jul 17

Gyre Therapeutics Adds CSO Yue Xiong, Max Kirkby, Claire Weston to Board Effective Aug. 1

Reuters
·
Jul 17

Movement Alert|Bristol-Myers Squibb Rises 3.01% in Regular Trading, Mezigdomide NDA Acceptance by FDA Continues to Boost Sentiment

Market Focus
·
Jul 17

Bristol Myers Squibb call volume above normal and directionally bullish

TIPRANKS
·
Jul 16

Bristol Myers Squibb Co. Stock Outperforms Competitors on Strong Trading Day

Dow Jones
·
Jul 16

Bristol-Myers Squibb Co Stock (BMY) Closed Up by 3.12% on Jul 15: Key Drivers Unveiled

TradingKey
·
Jul 16

BMY’s IZABRIGHT-Lung02 Trial Targets Growth in EGFR Lung Cancer

TIPRANKS
·
Jul 16

Movement Alert|Bristol-Myers Squibb Rises 3.02% in Regular Trading, FDA Accepts Mezigdomide New Drug Application Boosting Market Confidence

Market Focus
·
Jul 15

Septa Pharmaceuticals Inc. Acquires Ceenu® (lomustine) from Bristol Myers Squibb, Canada

THOMSON REUTERS
·
Jul 15

Berenberg Bank Sticks to Their Buy Rating for Bloomsbury Publishing (BMY)

TIPRANKS
·
Jul 15

Bristol-myers Squibb on Pace for Largest Percent Decrease Since November 2025

Dow Jones
·
Jul 15

Movement Alert|Bristol-Myers Squibb Falls 3.19% in Regular Trading, Broad Pharma Sector Weakness Amid Q2 Pricing Power Concerns

Market Focus
·
Jul 15

Agilent Wins FDA Approval for PD-L1 IHC 28-8 Test in Gastric and Esophageal Cancers

Reuters
·
Jul 14

Bristol Myers Squibb Co. Stock Outperforms Competitors on Strong Trading Day

Dow Jones
·
Jul 14

Bristol-Myers Squibb Co Stock (BMY) Closed Up by 3.07% on Jul 13: Key Drivers Unveiled

TradingKey
·
Jul 14

Movement Alert|Bristol-Myers Squibb Rises 3.12% in Regular Trading, FDA Accepts Mezigdomide New Drug Application for Myeloma

Market Focus
·
Jul 14

Bristol Myers Squibb Moves Closer to New Multiple Myeloma Treatment

Benzinga
·
Jul 14

Analysts Have Conflicting Sentiments on These Healthcare Companies: COMPASS Pathways (CMPS), NovoCure (NVCR) and Bristol-Myers Squibb (BMY)

TIPRANKS
·
Jul 13

FDA Accepts Bristol Myers NDA for Mezigdomide in Multiple Myeloma, Sets May 13, 2027 Decision Date

Reuters
·
Jul 13